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Background: Treatment with interferon-alpha (IFN-α) and ribavirin successfully clears hepatitis C virus (HCV)
infection in 50% of patients infected with genotype 1. Addition of NS3-4A protease inhibitors (PIs) increases
response rates but results in additional side effects and significant economic costs. Here, we hypothesised that
in vitro responsiveness of peripheral blood mononuclear cells (PBMCs) to IFN-α stimulation would identify patients
who achieved sustained virological response (SVR) on dual therapy alone and thus not require addition of PIs.
Methods: PBMCs were isolated from HCV infected patients (n = 42), infected with either HCV genotype 1 or
genotype 3, before commencing therapy and stimulated in vitro with IFN-α. Expression of the IFN stimulated genes
(ISGs) PKR, OAS and MxA was measured and correlated with subsequent treatment response and IL28B genotype.
Results: Genotype 1 infected patients who achieved SVR had significantly higher pre-treatment expression of PKR
(p = 0.0148), OAS (p = 0.0019) and MxA (p = 0.0019) in IFN-α stimulated PBMCs, compared to genotype 1 infected
patients who did not achieve SVR or patients infected with genotype 3, whose in vitro ISG expression did not
correlate with clinical responsiveness. IL28B genotype (rs12979860) did not correlate with endogenous or IFN-α
stimulated ISG responsiveness.
Conclusions: In vitro responsiveness of PBMCs to IFN-α from genotype 1 infected patients predicts clinical
responsiveness to dual therapy, independently of IL28B genotype. These results indicate that this sub-group of HCV
infected patients could be identified pre-treatment and successfully treated without PIs, thus reducing adverse side
effects and emergence of PI resistant virus while making significant economic savings.
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The standard of care for patients infected with hepatitis C
virus (HCV) for the past decade has consisted of dual
therapy with the anti-viral cytokine, interferon-alpha
(IFN-α) and the nucleoside analogue, ribavirin. IFN-α in-
duces anti-viral immunity by upregulating hundreds of
IFN stimulated genes (ISGs) [1], including many with po-
tent direct and indirect anti-viral activity [2]. Response
rates to therapy are highly variable, with patients infected* Correspondence: cliona.ofarrelly@tcd.ie
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unless otherwise stated.with genotype 1 (G1) having sustained virological response
(SVR) rates of less than 50%, whereas genotype 3 (G3) in-
fected patients can achieve SVRs of up to 82% [3].
Increased insight into the viral life cycle of HCV has led
to development of several new directly acting anti-viral
agents (DAAs), including NS3-4A protease inhibitors
(PIs). Several PIs, including telaprevir and boceprevir, are
administered in combination with standard IFN-α/ribavi-
rin treatment. Triple therapy increases response rates
from less than 50% to 75% in some G1 infected cohorts
[4,5]. However, PIs are expensive and associated with sig-
nificant additional side effects, such as anaemia and rash,
and emergence of drug resistant variants, a major challenge
in cases of non-compliance with therapy. Identification ofLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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therapy would obviate the need for additional PIs and alle-
viate these issues.
Multiple efforts have been made to accurately predict
response to therapy using viral and host characteristics.
Viral predictive markers include viral load and genotype,
while host predictive markers include age, sex, race, and
liver fibrosis stage [6]. Elevated serum levels of the chemo-
kine CXCL10 have also been reported to be associated
with non-response to IFN-α therapy [7]. Additionally, a
single nucleotide polymorphism (SNP), rs12979860, in
the recently described IFNλ4 gene [8] is highly predict-
ive of response [9,10]. The major C allele correlates
strongly with viral clearance particularly in patients in-
fected with HCV G1. Nevertheless, no single marker or
combination of markers accurately predicts patient
response in individual cases.
We hypothesised that in vitro responsiveness to IFN-α
would predict clinical responsiveness to dual therapy.
Hepatic ISG expression is elevated pre-treatment in pa-
tients who fail to achieve SVR [11] and has been shown to
be a stronger predictor of response than IL28B genotype
[12]. However, liver biopsy is an invasive procedure with
associated risks and has limited value as a prognostic tool.
Leukocytes are sensitive responders to IFN-α and provide
a more accessible alternative, requiring just a peripheral
blood sample. In fact, in vivo upregulation of ISGs in
PBMCs following therapeutic IFN-α is similar to ISG up-
regulation in vitro following IFN-α stimulation [13], sug-
gesting in vitro PBMC responsiveness may indeed be an
accurate reflection of in vivo clinical response.
IFN-α activates the JAK-STAT signalling pathway, lead-
ing to upregulation of over 500 ISGs [14]. PKR, OAS and
MxA are three well-characterised ISGs, strongly induced
by IFN-α in PBMCs, which have direct anti-viral action.
Activation of PKR by virus results in inhibition of protein
translation, including inhibition of viral mRNA translation
through phosphorylation of the alpha subunit of eukaryotic
protein synthesis initiation factor 2 (eIF2α) [15]. Indeed,
HCV has evolved several mechanisms to block the action
of this important regulator of translation [16,17]. OAS is
an IFN regulated activator of latent ribonuclease RNase L,
which is triggered by activated OAS to directly cleave
RNA, including HCV RNA, thus destroying viral RNA
products and producing pathogen associated molecular
patterns (PAMPs) that further stimulate innate immune
activity [18,19]. MxA recognises viral nucleocapsids and
renders them redundant by wrapping around the viral
structure and forming MxA/nucleocapsid oligomers [20].
MxA may also direct nucleocapsids to alternative sites in
the cytoplasm, where they are not functional for RNA syn-
thesis and likely to be immobilised and subsequently de-
graded [2]. Interestingly, we have demonstrated that the
core protein of HCV co-localises with MxA in a granularpattern in the cytoplasm of cells, a phenomenon that is po-
tentiated with the co-treatment of IFN-α and ribavirin
[21]. Hepatic expression of MxA is a known predictor of
response to IFN-α therapy [22,23]. Because of their role as
key mediators of IFN-α-induced antiviral activity, PKR,
OAS and MxA were chosen as potential indicators of IFN-
α treatment responsiveness in this prospective study.
Prior to treatment, we measured in vitro responsive-
ness of PBMCs to IFN-α stimulation by quantifying
PKR, OAS and MxA expression levels in IFN-α treated
PBMCs isolated from HCV infected patients. We corre-
lated ISG expression with the patient’s subsequent clin-




Patients (n = 41) from St. Vincent’s University Hospital
(SVUH) and St. James’s Hospital Dublin (SJH), who were
mono-infected with HCV, were recruited. Written con-
sent was obtained from each patient and ethical approval
was obtained from the ethics and medical research com-
mittee at SVUH and the research ethics committee at
SJH, in accordance with the ethical guidelines of the
1975 Declaration of Helsinki. Patients were treated with
pegylated IFN-α2a or IFN-α2b in combination with riba-
virin as previously described [24]. Patients who were
HCV-RNA negative at week 4 of treatment were termed
rapid virological responders (RVR); patients with a 2 log
drop in viral RNA by week 12 were termed early viro-
logical responders (EVR); HCV-RNA –ve patients at the
end of treatment were classed as having an end-of-
treatment response (EOT); patients who were HCV-
RNA 6 months post treatment achieved SVR; and those
who were HCV-RNA at EOT but had viral breakthrough
6 months post treatment were termed relapsers.
PBMC preparation and stimulation
Blood samples were collected in lithium heparin tubes and
PBMCs were freshly isolated by density centrifugation using
Ficoll-Paque separation medium (GE Healthcare, Sweden).
2 × 106 PBMCs per ml of RPMI, supplemented with 10%
FCS and 250 U/ml penicillin, 250 μg/ml streptomycin, were
cultured at 37°C, and stimulated fresh with 100 IU or
1000 IU pegylated IFN α-2a (Roche, Switzerland) for 2 and
4 hours. PBMCs were immediately lysed in Trizol reagent
(Invitrogen, USA) following stimulation, thus preserving
the RNA and stored at −80°C until analysis.
RNA Extraction and Quantitative Real-time PCR (qRT-PCR)
RNA was extracted according to manufacturer’s instruc-
tions and reverse transcribed using Omniscript (Invitro-
gen). qRT-PCR using SyBr green was performed on an
MX3000P® system (Stratagene Corp, USA) using the
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1 min and 72°C for 30 sec. Following geNORM analysis of
a panel of housekeepers, the most stable housekeeping gene
was found to be ribosomal protein 15 (RPS15) [25]. Gene
amplifications were normalised to RPS15 and expressed on
a log scale [26]. Primers are shown in Table 1.IL28B SNP analysis
Rs12979860 genotype was determined from patient
blood or serum samples using the LightMix Kit IL28B
(Roche/Tib MolBiol).Table 2 Clinical features
Feature Genotype 1 Genotype 3 P value*
Patients (n) 18 23 0.7§
Males, n (%) 13 (68) 15 (65) 1§
Females, n (%) 6 (32) 8 (35)
Age (years −/+SD) 44.6 −/+13.2 43.2 −/+10.2 0.19¶Statistical analysis
Paired samples were analysed using Wilcoxon matched-
pairs rank tests; for unpaired samples, non-parametric
Mann–Whitney U tests and Fisher’s exact test were used.
Area under the curve (AUC) analysis was calculated from
receiver operating characteristics (ROC) curve. P values
<0.05 were considered statistically significant.Risk factors, n (%)
Injecting drug use 7 (39) 12 (52) 0.53§
Blood transfusion 4 (22) 2 (9) 0.03§
Anti-D immunoglobulin 4 (22) 0 (0) 0.38§
Not determined 3 (17) 9 (39) 0.17§
Liver enzyme levels
ALT (IU/L −/+SD) 112.8 −/+122.6 107.4 −/+86.3 0.34¶
AST (IU/L −/+SD) 66.6 −/+54.8 69.2 −/+59.5 0.5¶
Leukocyte counts
WCC (x 109/L −/+SD) 5.7 −/+2 6.4 −/+2.5 0.3¶
Neutrophils (x103/μl) 3.3 −/+1.4 3.4 −/+1.7 0.99¶
Lymphocytes (x103/μl) 1.8 −/+0.6 2.3 −/+1 0.06¶
Monocytes (x103/μl) 0.46 −/+0.13 0.6 −/+0.3 0.17¶
Viral load (x106 IU/ml −/+) SD) 5.6 −/+10.8 7.5 −/+1.3 0.31¶
IL-28B genotype n (%)
CC 4 (22) 8 (35) 0.5§
CT/TT 10 (56) 9 (39) 0.36§
Not determined 4 (22) 6 (26) 1§
*Comparison between G1 and G3 infected patients.
§Fisher’s exact test.
¶Mann–Whitney U test.
ALT alanine aminotrasferase, AST aspartate aminotransferase, WCC white
cell count.Results
Patient characteristics
Forty-one patients with chronic HCV infection were stud-
ied prospectively, the majority of whom had been infected
via IV drug use (Table 2). Eighteen patietns were infected
with genotype1 (G1) and 23 with genotype 3 (G3). Num-
bers of patients, gender ratios and ages were similar in
both groups. Demographic, clinical, virological and genetic
features were also similar. Liver enzyme levels (ALT p =
0.34, AST p = 0.5), viral load (p = 0.31) and IL28B geno-
type (CC p = 0.5, CT/TT p = 0.36) were similar in both
groups. Circulating lymphocytes tended to be lower in G1
infected patients (1.8 × 103/μl) when compared with G3
infected patients (2.3 × 103/μl) but this difference was not
significant (p = 0.06). Total white cell counts, neutrophil
and monocyte counts were similar in both patient cohorts.
Of the 41 patients recruited, 36 successfully completed
therapy (G1 n = 16, G3 n = 20). Surprisingly, in this study
there was no significant difference in response rates
between G1 or G3 infected patients recruited (Table 3;
RVR 42% vs 57% respectively, p = 0.54; EVR 83% vs
90% p = 0.64; EOT 72% vs 86% p = 0.68; SVR 56% vs
65% p = 0.74).Pre-treatment ISG expression in PBMCs predicts SVR in
G1, but not G3, infected patients
To determine whether in vitro responsiveness of PBMCs
to IFN-α could predict clinical response to therapeutic
IFN-α, PBMCs were isolated from patients before they
commenced therapy, stimulated in vitro with IFN-α and
ISG expression was quantified. G1 infected patients who
successfully achieved SVR following treatment had signifi-
cantly higher induction of PKR (p = 0.0148), OAS (p =
0.0019) and MxA (p = 0.0019; Figure 1B) following stimu-
lation with IFN-α compared to G1 infected patients who
failed to achieve SVR. As well as having higher induction
of these ISGs following in vitro IFN-α stimulation, G1
Table 3 Clinical response to treatment
Therapeutic outcome Genotype 1 Genotype 3 P value§
RVR (%) 8 (42) 13 (57) 0.54
EVR (%) 15 (83) 20 (90) 0.64
EOT (%) 13 (72) 19 (86) 0.68
SVR (%) 10 (62.5) 13 (65) 0.74
Relapse (%) 3 (23) 6 (33) 1
§Fisher’s exact test.
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dogenous levels of PKR and MxA (p = 0.0281 and p =
0.0207 respectively; Figure 1A). Conversely, pre-treatment
endogenous or IFN-α induced ISG expression was not
consistently higher in G1 infected patients who achieved
RVR (Additional file 1: Figure S1), EVR (Additional file 1:
Figure S2) or EOT response (Additional file 1: Figure S3)
compared to those who did not. Therefore, in G1 infected
patients, enhanced ISG expression only correlated with
SVR and not with other on-treatment response rates. In
contrast to G1 infected patients, G3 infected patients
showed no correlation with either endogenous ISG expres-
sion (PKR p = 0.8107, OAS p = 0.3106, MxA p= 0.5740;Figure 1 G1 infected patients who achieve SVR have higher ISG expre
from G1 infected patients pre-treatment and stimulated with IFN-α. qRT-PC
induction of ISGs. Gene expression was normalised to expression of RPS15 andFigure 2A) or IFN-α stimulated ISG expression (PKR p =
0.9307, OAS p = 0.4833, MxA p = 0.2103; Figure 2B) and
achieving an SVR.
To determine the predictive value of IFN-α responsive-
ness in G1 infected patients, ROC curves were calculated
based on ISG expression following stimulation with IFN-
α. PKR expression had an AUC of 0.86 (p = 0.016) while
both OAS and MxA each had an AUC of 0.94 (p = 0.003)
(Additional file 1: Table S1). We used predictive values of
gene cut-off expression levels (generated from the AUC
analysis) to evaluate which patients would respond to dual
therapy and thus not require additional PIs. Of all three
genes examined, MxA had the strongest predictive power,
with a PPV of 100%, a NPV of 88.9% and a likelihood ratio
of 8 based on a cut-off of 91.2, despite the low numbers of
patients in the analysis.
Univariate analysis was used to determine whether
other pre-treatment characteristics were predictive of
treatment response in our G1 and G3 infected cohorts
(Table 4). In G1 infected patients, PKR, OAS and MxA
induction was the only significant predictor of SVR.
Lack of response to therapy was not associated with al-
tered numbers of white blood cells. In G3 infectedssion pre-treatment than those without SVR. PBMCs were isolated
R was used to quantify (A) endogenous and (B) IFN-α stimulated
expressed on a log scale. Data were analysed using Mann–Whitney U-tests.
Figure 2 ISG expression is not predictive of treatment response in patients infected with HCV g3. PBMCs were isolated from G3 infected
patients pre-treatment and stimulated with IFN-α. qRT-PCR was used to quantify (A) endogenous and (B) IFN-α stimulated induction of ISGs.
Gene expression was normalised to expression of RPS15 and expressed on a log scale. Data were analysed using Mann–Whitney U-tests.
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lower pre-treatment viral load (p = 0.045) and younger
age (p = 0.03). Achieving RVR (p = 0.06), and high pre-
treatment lymphocyte numbers (p = 0.07) were also close
to being significantly associated with SVR in this cohort.
Rs12979860 genotype does not affect ISG expression in
PBMCs from HCV infected patients
In other studies, the SNP (rs12979860) in the IFNλ4
gene, some distance from the IL28 genes, is highly pre-
dictive of treatment response [10,27]. ISG expression in
liver tissue from HCV infected patients has been shown
to correlate with rs12979860 genotype [12]. We there-
fore investigated whether rs12979860 genotype influ-
enced ISG expression in PBMCs from HCV infected
individuals in our study. IFN-α stimulation of PBMCs
led to robust upregulation of ISG expression, regardless
of whether patients carried the minor T allele for
rs12979860 (Figure 3A), demonstrating that in vitro in-
duction of IFN-α stimulated ISGs in PBMCs was inde-
pendent of IL28B genotype. Additionally, rs12979860
genotype did not influence endogenous ISG levels in
PBMCs. When ISG expression in patients who achieved
SVR was compared to those who did not, and stratified
based on rs12979860 genotype, there were no significantdifferences observed between patients with CC or CT/
TT genotype (Figure 3B). There was also no difference
in ISG expression and IL28B genotype between G1 and
G3 infected patients (Figure 4).
Discussion
Approximately 50% of HCV infected patients infected
with G1 achieve an SVR with IFN-α and ribavirin therapy
and do not actually need additional PIs in their treatment
regime. However, it has it has not hitherto been possible
to identify responsive patients prior to commencing treat-
ment. Here, we hypothesised that in vitro analysis of im-
mune cell responsiveness to IFN-α stimulation prior to
treatment would predict clinically responsive patients. In
this prospective study, we found that G1 infected patients
who achieved SVR could indeed be identified prior to
treatment by the significantly greater ISG induction in
their PBMCs following in vitro IFN-α stimulation than in
PBMCs from G1 infected patients who did not achieve
SVR. Interestingly, this finding seems to be exclusive to
patients infected with GI as the clinical response of G3 in-
fected patients could not be predicted pre-treatment.
IL28B genotype did not influence ISG expression in
PBMCs nor in vitro IFN-α stimulated responses and there
was no difference in ISG expression between patients who
Table 4 Univariate analysis of predictors of SVR in g1 and g3 infected patients
Genotype 1 infected patients SVR (n = 8) No SVR (n = 8) P value
Age (years −/+SD) 40.9 −/+4.2 47.3 −/+5.6 0.4¶
Sex (m/f) 6/2 4/4 0.61§
IL28B genotype (CC/CT or TT)* 5/3 5/1 0.58§
Fibrosis 2.5 −/+0.9 1.7 −/+0.6 0.59¶
RVR (Y/N) 4/4 2/6 0.61§
Viral load (x106) 2.1 −/+1.1 5.6 −/+3.1 0.65¶
Liver enzyme levels
ALT 87 −/+26.6 44.1 −/+8.6 0.57¶
AST 162.3 −/+58.2 53.3 −/+8.9 0.19¶
Leukocyte counts
White cell count 5.6 −/+1 5.9 −/+0.5 0.56¶
Neutrophils 3.2 −/+0.7 3.3 −/+0.4 0.8¶
Lymphocytes 1.8 −/+0.3 1.9 −/+0.2 0.68¶
Monocytes 0.5 −/+0.1 0.4 −/+0.05 0.72¶
ISG expression
PKR endogenous 3.3 −/+1.1 0.7 −/+0.1 0.028¶
OAS endogenous 2.6 −/+0.8 0.7 −/+0.2 0.19¶
MxA endogenous 8.1 −/+3.2 1.3 −/+0.5 0.021¶
PKR induction 41.1 −/+9.2 10.8 −/+2.8 0.015¶
OAS induction 51 −/+19.3 8.8 −/+3.4 0.002¶
MxA induction 235 −/+52.5 29.7 −/+10.6 0.002¶
Genotype 3 infected patients SVR (n = 13) No SVR (n = 7) P value
Age (years −/+SD) 39.6 −/+1.9 47 −/+2.4 0.03¶
Sex (m/f) 7/6 5/2 0.64§
IL28B genotype (CC/CT or TT)* 4/5 4/3 1§
RVR (Y/N) 10/3 2/5 0.06§
Viral load (x106) 7.8 −/+3.8 9.6 −/+3.6 0.045¶
Liver enzyme levels
ALT 93 −/+17 147 −/+38 0.24¶
AST 58.2 −/+9.8 109 −/+25.6 0.13¶
Leukocyte counts
White cell count 6.6 −/+0.7 5.8 −/+0.8 0.37¶
Neutrophils 3 −/+0.5 3.1 −/+0.5 0.76¶
Lymphocytes 2.7 −/+0.3 1.9 −/+0.2 0.07¶
Monocytes 0.6 −/+0.1 0.5 −/+0.1 0.71¶
ISG expression
PKR endogenous 2.1 −/+0.5 2 −/+1 0.81¶
OAS endogenous 2.2 −/+1 2 −/+0.6 0.31¶
MxA endogenous 11.4 −/+4.4 8.1 −/+3.2 0.57¶
PKR induction 29.1 −/+6.9 29.5 −/+9.6 0.93¶
OAS induction 23.9 −/+8 70.6 −/+36.8 0.48¶
MxA induction 126 −/+34 226.4 −/+81.2 0.21¶
RVR rapid virological response, ALT alanine aminotrasferase, AST aspartate aminotransferase.
*Data not available for all patients included in study.
§Fisher’s exact test.
¶Mann–Whitney U test.
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Figure 3 rs12979860 genotype is independent of ISG expression in PBMCs from HCV infected patients. PBMCs were isolated from HCV
infected patients pre-treatment and stimulated with IFN-α. qRT-PCR was used to quantify endogenous and IFN-α induced expression of ISGs. ISG
expression was stratified based on (A) rs12979860 genotype and (B) rs12979860 genotype and treatment response. Gene expression was normal-
ised to expression of RPS15 and expressed on a log scale. Each dot represents one sample and median gene expression is shown. Data were ana-
lysed using Wilcoxon matched-pairs rank test and Mann–Whitney U-tests; N/D = not determined due to low n number.
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IL28B genotypes.
The development of DAAs is an exciting advance in
treating HCV infection and offers many genotype 1 in-
fected patients who would not respond to standard IFN-α
therapy, additional options for treatment. However, cur-
rently licensed PIs are given in combination with dual
IFN-α therapy, thus significantly increasing costs and
introducing additional significant side effects. Trials in-
volving DAAs in “IFN free” regimes are extremely promis-
ing for certain groups of patients, however IFN-α therapy
still boasts a lack of drug-drug interactions, relatively low
cost, lack of effect of viral resistant mutants and a long
clinical track record [28]. Crucially, the cost of DAAs will
prevent their large scale distribution in low and middle in-
come countries, which have the highest rates of HCV in-
fection, for the foreseeable future. Therefore, identification
of subgroups of patients who would not require additional
PIs would make significant economic savings.
Several predictors of response to dual therapy have pre-
viously been described including demographic, genetic
and intrahepatic markers [3]. Studies have shown hepatic
ISG expression to be a strong predictor of treatmentresponse [11,29]. Using microarrays, others have shown
that global transcriptional responses in PBMCs following
in vivo and ex vivo IFN-α stimulation are different be-
tween responders and non-responders following treatment
[30,31]. We found that G1 infected patients who achieved
an SVR had significantly higher ISG expression in PBMCs
prior to treatment. Pre-treatment, endogenous expression
of PKR and MxA was lower in PBMCs from G1 infected
patients who failed to achieve an SVR, contrasting with pre-
vious reports from the liver showing elevated pre-treatment
ISG expression predictive of therapeutic non-responsive
[11]. A range of IFN-sensitive mechanisms may already be
activated in HCV-infected liver, which harbours mixed pop-
ulations of cells including epithelial and endothelial cells as
well as hepatocytes and immune cells. In comparison,
PBMCs provide a more accessible homogenous population
for use as a resource for identifying patients who are re-
sponsive to IFN-α.
Interestingly, pre-treatment ISG expression in PBMCs
from G3 infected patients could not predict SVR, yet ISG
expression was strongly predictive of therapeutic response
in G1 infected patients, suggesting that HCV G1 may dif-
fer significantly from G3 in its ability to target IFN-α
Figure 4 ISG expression, stratified based on IL28B genotype, is similar between G1 and G3 infected patients. PBMCs were isolated from
HCV infected patients prior to them commencing IFN-α therapy and were stimulated in vitro with 1000 IU of IFN-α for 4 h. qRT-PCR was used to
quantify endogenous and IFN-α stimulated expression of ISGs. ISG expression was stratified based on rs12979860 genotype and (A) endogenous
and (B) IFN-α stimulated ISG expression was measured. All gene expression was normalised to expression of the internal control gene RPS15 and
expressed on a log scale. Each dot represents one sample and median gene expression is shown. Data were analysed using Wilcoxon
matched-pairs rank test and Mann–Whitney U-tests.
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protease, are known inhibitors of the IFN response
[32,33]. We recently found that HCV G1 degrades signal
transducers and activator of transcription 1 (STAT1) and
STAT3, key transcription factors activated by IFN-α sig-
nalling, and showed that this suppression was consistent
across all PBMC subsets [34]. However, it is possible that
HCV genotypes differentially target IFN-α signalling per-
haps explaining the differences in ISG expression we ob-
served in G1 and G3 infected patients.
Patients who have rapid decreases in viral load and
achieve an RVR have a 90% chance of achieving overall
SVR [35]. However, we found that pre-treatment ISG ex-
pression was not strongly associated with RVR, suggesting
that ISG expression in PBMCs is independent of RVR, in
accordance with a study by Sarasin-Filipowicz et al. [29].
That study did not examine SVR. Unusually, RVR was not
predictive of overall SVR in our G1 infected cohort. Al-
though ISG expression tended to be higher in patients who
achieved EVR or were PCR –ve at the end of treatment
compared to RVR in G1 infected patients, the strongestassociation seen was that between pre-treatment ISG ex-
pression and SVR.
In this study, we analysed expression of three well-
defined anti-viral genes (PKR, OAS and MxA) that have
been shown using microarray analysis to be upregu-
lated in PBMCs and specific immune cell subsets, in-
cluding macrophages, DCs and NK cells, following
in vitro IFN-α stimulation [2,36-39]. IFN-α is a strong
regulator of gene expression in PBMCs and Zimmerer
et al. demonstrated that in vitro stimulation of PBMCs
mimics in vivo effects [40]. This study also demon-
strated that T cells, monocytes and NK cells all respond
to in vitro IFN-α stimulation. Recently, a retrospective
analysis of G1 infected HCV patients of mixed race
demonstrated that SVR and monocyte activation in re-
sponse to 24 h in vitro stimulation with IFN-α were
negatively correlated but failed to show any correlation
between IFN-α induced myeloid and plasmacytoid den-
dritic cell activation and therapeutic response. In our
study, we found enhanced responses to 4 h in vitro
stimulation in unseparated PBMCs from G1 infected
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ation of IFN-α stimulation is critical.
The rs12979860 SNP, located upstream of the IL28B
gene and present in the novel IFNλ4 gene [8], is a robust
predictor of spontaneous viral clearance and response to
treatment in some cohorts [9,10]. Of note, hepatic ISG ex-
pression has also been shown to be a stronger predictor of
response than IL28B genotype [12,22]. The predictive
value of IL28B is increased when combined with the pre-
dictive power of other known indicators of response, such
as serum CXCL10 levels [41]. Amongst our G1 infected
patients, ISG expression in PBMCs was more predictive of
therapeutic response than IL28B genotype which was a
surprising result given the strong predictive power of this
SNP in other studies [10,27]. However, it is possible that
the IL28B genotype is not a strong predictor in all cohorts;
indeed MxA staining in hepatic macrophages has been
found to be a better predictor of SVR than IL28B genotype
in a Canadian cohort [22]. Endogenous ISG expression
has been shown to be higher in livers from patients carry-
ing the minor T allele for rs12979860 [12], yet we found
that in PBMCs, ISG expression was similar between pa-
tients of any genotype. Microarray studies have shown that
ISG expression in PBMCs from G1 infected patients was
independent of IL28B genotype [42]. In a HCV/HIV co-
infected cohort of patients, induction of ISGs following
12 hours of in vivo stimulation with IFN-α, was independ-
ent of IL28B genotype, echoing our findings in PBMCs
from HCV infected patients.
Conclusions
In vitro responsiveness of PBMCs from G1 infected pa-
tients to IFN-α stimulation pre-treatment identifies pa-
tients who will achieve SVR on dual therapy. These
patients do not need additional PIs to clear the virus.
Reliable identification of patients who do not require
triple therapy would provide significant cost benefits, re-
duce side effects and halt the emergence of PI resistant
strains of virus.
Additional file
Additional file 1: Figure S1. Correlation between RVR and ISG
expression. PBMCs were stimulated in vitro with 100 IU or 1000 IU of
IFN-α for 2 or 4 h. qRT-PCR was used to quantify ISG expression. Analysis
stratified into those who achieved RVR and those who did not. (A) all viral
genotypes, (B) g1 infected patients and (C) g3 infected patients. All gene
expression was normalised to expression of RPS15 and expressed on a log
scale. Mann-Whitney statistical analysis, *p<0.05. Figure S2. Correlation
between EVR and ISG expression. PBMCs were stimulated in vitro with
100 IU or 1000 IU of IFN-α for 2 or 4 h. qRT-PCR was used to quantify ISG
expression. Analysis stratified into those who achieved EVR and those who
did not. (A) all viral genotypes (B) g1 infected patients and (C) g3 infected
patients. All gene expression was normalised to expression of RPS15 and
expressed on a log scale. Mann-Whitney statistical analysis, *p<0.05.
Figure S3. Correlation between EOT response and ISG expression. PBMCs
were stimulated in vitro with 100 IU or 1000 IU of IFN-α for 2 or 4 h. qRT-PCR was used to quantify ISG expression. Analysis stratified into those
who were PCR –ve at EOT and those who were PCR +ve. (A) all viral
genotypes, (B) g1 infected patients and (C) g3 infected patients. All gene
expression was normalised to expression of RPS15 and expressed on a
log scale. Mann-Whitney statistical analysis, *p<0.05, **p<0.01. Table S1.
Predictability of SVR based on cut-off gene expression values. Gene cut-off
values quantified following 4h in vitro IFN-α stimulation, as determined by
qRT-PCR, were analysed to predict response of g1 infected patients to respond
to therapeutic IFN-α using receiver operating characteristic (ROC) analysis.
AUC: area under curve in ROC analysis, CI: confidence intervals, PPV: positive
predictive value, NPV: negative predictive value.
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